GLP-1 Medication Guide

The patient notebook

A little clarity, one question at a time.

Open the source shelf ↗

Promotional #2

SuperHealthy Rx

Compounded medication offer

SuperHealthy Rx's checked GLP-1 offer page presents a bundled program with compounded medication, clinical review and shipping. The advertised figures are $85 per month for semaglutide and $135 for tirzepatide. Put a date next to these numbers in your notes: October 5, 2026. The page still contains seasonal sale wording, so we cannot promise the promotion remains available at a later checkout.

Clarify the refill choice

The offer describes automatic refills as optional and says there is no separate membership fee. Ask what your selected setting means in practice: whether another order is scheduled, when it would be billed and how to stop a future refill. Keep a copy of the answer alongside the plan details rather than relying on the headline alone.

A bundled offer can make the price easier to read, but it does not answer every care question. Ask how clinical follow-up works and how to reach a qualified professional when the medicine arrives. A customer-support contact and a clinical contact may serve different purposes.

Ask for names, not just categories

The page refers to the MD Integrations clinical network and licensed US pharmacies. Those are provider statements; the offer page does not identify the pharmacy that would fill a particular patient's prescription. Ask for that name and verify the dispensing information when it becomes available.

Compounded products are not FDA-approved. Discuss the reason for using one with the prescribing clinician. Our #2 placement reflects the publisher's promotional choice. It is not a guarantee of eligibility, delivery time or treatment results, and our desk has not used the service as a patient.

Sources for this note

Checked October 5, 2026. Provider sources describe advertised offers; they do not independently establish quality of care.

  1. SuperHealthy Rx — current GLP-1 offerProvider offer
  2. FDA — concerns with unapproved GLP-1 drugsRegulator guidance